WO2008039983A3 - Methods and compositions using mutant gp120 - Google Patents

Methods and compositions using mutant gp120 Download PDF

Info

Publication number
WO2008039983A3
WO2008039983A3 PCT/US2007/079890 US2007079890W WO2008039983A3 WO 2008039983 A3 WO2008039983 A3 WO 2008039983A3 US 2007079890 W US2007079890 W US 2007079890W WO 2008039983 A3 WO2008039983 A3 WO 2008039983A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
mutant
amino acids
acids deleted
Prior art date
Application number
PCT/US2007/079890
Other languages
French (fr)
Other versions
WO2008039983A2 (en
Inventor
Stephen C Harrison
Bing Chen
Original Assignee
Harvard College
Stephen C Harrison
Bing Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Stephen C Harrison, Bing Chen filed Critical Harvard College
Publication of WO2008039983A2 publication Critical patent/WO2008039983A2/en
Publication of WO2008039983A3 publication Critical patent/WO2008039983A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compositions and methods for eliciting an immune response against HIV and/or SIV are provided. Isolated gpl20 proteins having two or more amino acids deleted from their β3-β5 loop regions and isolated nucleic acid sequences encoding a gpl20 protein having two or more amino acids deleted from its β3-β5 loop region are also provided.
PCT/US2007/079890 2006-09-28 2007-09-28 Methods and compositions using mutant gp120 WO2008039983A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84773806P 2006-09-28 2006-09-28
US60/847,738 2006-09-28

Publications (2)

Publication Number Publication Date
WO2008039983A2 WO2008039983A2 (en) 2008-04-03
WO2008039983A3 true WO2008039983A3 (en) 2008-11-13

Family

ID=39231011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/079890 WO2008039983A2 (en) 2006-09-28 2007-09-28 Methods and compositions using mutant gp120

Country Status (1)

Country Link
WO (1) WO2008039983A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792459A (en) * 1988-09-13 1998-08-11 Chiron Corporation HIV-1 envelope muteins lacking hypervariable domains

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792459A (en) * 1988-09-13 1998-08-11 Chiron Corporation HIV-1 envelope muteins lacking hypervariable domains

Also Published As

Publication number Publication date
WO2008039983A2 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
WO2008063331A3 (en) Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
WO2007024941A3 (en) Polyvalent vaccine
WO2006059093A3 (en) Fusion proteins
WO2009059195A3 (en) Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
WO2006069262A3 (en) Compositions of influenza viral proteins and methods of use thereof
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
WO2006066258A3 (en) Lipoconjugation of peptides
WO2006074233A3 (en) Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
WO2008115199A3 (en) Chimeric virus vaccines
WO2004094466A3 (en) Recombinant influenza viruses holding a mutation in a transmembrane protein gene
WO2005118813A3 (en) Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
WO2003020932A1 (en) Novel secretory proteins and dna thereof
WO2003072746A3 (en) Subtilisin carlsberg proteins with reduced immunogenicity
WO2007008527A3 (en) Chimeric vaccine for haemophilus influenzae-induced disease
EP1652857A3 (en) Fusion protein of HIV regulatory/accessory proteins
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
WO2005110492A3 (en) Method of using adenoviral vectors to induce an immune response
WO2005000884A8 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
WO2004103269A3 (en) Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia
WO2006127822A3 (en) Scytovirin domain 1 related polypeptides
WO2005060350A8 (en) Diastereomeric peptides useful as inhibitors of membrane protein assembly
WO2005018552A3 (en) Heparin binding proteins: sensors for heparin detection
WO2007020520A3 (en) Antigenic peptides and their use
WO2001094949A3 (en) Soluble cd1 compositions and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07843484

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07843484

Country of ref document: EP

Kind code of ref document: A2